Cargando…

Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density

BACKGROUND AND OBJECTIVE: Abaloparatide, an anabolic osteoporosis treatment administered by subcutaneous (SC) injection, increases bone mineral density (BMD) and reduces fracture risk in postmenopausal women with osteoporosis. The abaloparatide-solid Microstructured Transdermal System [abaloparatide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Paul D., Troy, Steven, Weiss, Richard J., Annett, Miriam, Schense, Jason, Williams, Setareh A., Mitlak, Bruce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946681/ https://www.ncbi.nlm.nih.gov/pubmed/33638863 http://dx.doi.org/10.1007/s40261-021-01008-7

Ejemplares similares

OR03-1 The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
por: Lane, Nancy, et al.
Publicado: (2019)

Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis
por: Dempster, David W, et al.
Publicado: (2021)

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
por: Leder, Benjamin Z, et al.
Publicado: (2019)

Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
por: Watts, N.B., et al.
Publicado: (2019)

Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial
por: Cosman, Felicia, et al.
Publicado: (2020)

Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis
por: Tella, Sri Harsha, et al.
Publicado: (2017)

Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
por: Watts, N. B., et al.
Publicado: (2020)

Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
por: Watts, N. B., et al.
Publicado: (2020)

Abaloparatide Real‐World Patient Experience Study
por: Gold, Deborah T, et al.
Publicado: (2021)

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
por: Bone, Henry G, et al.
Publicado: (2018)

Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
por: McClung, Michael R., et al.
Publicado: (2017)

Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
por: Dhaliwal, Ruban, et al.
Publicado: (2020)

Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice()
por: Arlt, Heike, et al.
Publicado: (2020)

Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis
por: Hong, Pan, et al.
Publicado: (2023)

SAT-519 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture Representative of Covered Commercial Insurance Enrollees
por: Saag, Kenneth, et al.
Publicado: (2019)

Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
por: Dhaliwal, Ruban, et al.
Publicado: (2020)

Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
por: McClung, Michael R., et al.
Publicado: (2018)

Abaloparatide and the Spine: A Narrative Review
por: Thompson, Jeremy C, et al.
Publicado: (2020)

Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study
por: Cosman, F., et al.
Publicado: (2022)

Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia
por: Chandler, H., et al.
Publicado: (2019)

OR03-2 Different Effects of Abaloparatide and h-PTH(1-34) on Osteoclastogenesis and Bone Resorption
por: Arlt, Heike, et al.
Publicado: (2019)

Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend
por: Deal, Chad L., et al.
Publicado: (2019)

Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend
por: Greenspan, Susan L., et al.
Publicado: (2020)

ERRATUM for “Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis”
Publicado: (2020)

The Efficacy and Safety of Abaloparatide‐SC in Men With Osteoporosis: A Randomized Clinical Trial
por: Czerwinski, Edward, et al.
Publicado: (2022)

Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE
por: Eastell, R., et al.
Publicado: (2019)

302 Abaloparatide as a novel therapy for posttraumatic osteoarthritis
por: Landgrave, Samantha H., et al.
Publicado: (2022)

Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide
por: Reginster, Jean-Yves, et al.
Publicado: (2018)

Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis
por: Reginster, J. -Y., et al.
Publicado: (2019)

Teriparatide and Abaloparatide Have a Similar Effect on Bone in Mice
por: Brent, Mikkel Bo, et al.
Publicado: (2021)

Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats
por: Bahar, Hila, et al.
Publicado: (2016)

The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar
por: Brent, Mikkel Bo, et al.
Publicado: (2020)

Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
por: Leder, Benjamin Z, et al.
Publicado: (2019)

SUN-335 Abaloparatide Prevents Unloading-Induced Bone Loss in Adult Rats
por: Teguh, Dian A, et al.
Publicado: (2020)

Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling
por: Winzenrieth, R., et al.
Publicado: (2021)

Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States
por: Hiligsmann, Mickaël, et al.
Publicado: (2023)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability
por: McCloskey, E. V., et al.
Publicado: (2019)

Abaloparatide versus teriparatide: a head to head comparison of effects on fracture healing in mouse models
por: Bernhardsson, Magnus, et al.
Publicado: (2018)

Abaloparatide Has the Same Catabolic Effects on Bones of Mice When Infused as PTH (1–34)
por: Le Henaff, Carole, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fl6d8dt26oghtjobqrrjuko66c